SBIR-STTR Award

DNA screening assay for human herpes virus
Award last edited on: 6/3/02

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$48,317
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Frank A White III

Company Information

SRA Life Sciences (AKA: SRA Technologies Inc)

8110 Gatehouse Road Suite 600
Falls Church, VA 22042
   (703) 205-8500
   N/A
   N/A
Location: Single
Congr. District: 08
County: Fairfax

Phase I

Contract Number: 1R43AI034281-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1993
Phase I Amount
$48,317
Herpesvirus-6 (HHV-6) is a human pathogen that causes exanthem subitem (roseola) in children and appears to be associated with AIDS, tissue transplants and transplant rejection, various autoimmune diseases, Iymphomas Kaposi's sarcoma and other tumors, hepatitis, chronic fatigue syndrome, and several other diseases. Multiple strains of HHV-6 have been detected and categorized into two proposed groups. Unequivocal evidence is needed that HHV-6 is actually two or more closely related viruses, that each type is associated with different diseases, and that both types of HHV-6 can establish a latent infection in humans. The goal of the research is to develop reagents for assessing various HHV-6 strains in clinical samples. We have recently developed a novel, high-throughput assay for distinguishing between different strains of virus by a single base pair resolution method. We propose to apply this assay to samples ot~ HHV-6 amplified from clinical samples by use of the polymerase chain reaction (PCR) method. Products will be detected with chemiluminescent probes, which are as sensitive as p32-labelled probes and more sensitive than fluorescent ones. In Phase I, we plan to adapt these methods to a rapid, economical assay for screening the two major strains of HHV-6 in clinical samples. In Phase 11, we will refine and extend these procedures for distinguishing among the subtypes of HHV-6 that have been detected in infected clinical specimens of blood, saliva, urine, and tissue. Awardee's statement of the potential commercial applications of the research: We propose to develop a rapid and economical large-scale screening assay for distinguishing between different strains of human herpesvirus-6 (HHV-6) in clinical samples. Detection of HHV-6 sequences amplified by the polymerase chain reaction utilizes a novel microtiter plate assay and a highly sensitive chemiluminescent substrate to detect, by probe hybridization, sequences unique to a particular strain or subtype of HHV-6.National Institute of Allergy and Infectious Diseases (NIAID)

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----